FDA-funded report on compounded hormones is tainted, analysis showsPublished April 23, 2021
A 2020 FDA-funded report published by the National Academies of Science, Engineering, and Medicine on the safety and utility of compounded hormones is compromised by potential bias, conflicts of interest and bad science — so says an independent, third-party analysis.
FDA touted the NASEM report, which recommended restrictions on compounded hormone therapy, as “independent” and “comprehensive,” but in fact it was neither. That’s one of the key findings in the white paper by Dr. Alyson Wooten, a director at the nonpartisan Berkeley Research Group (BRG).
The paper, The Panel Put Policy-Making Before Patient Need: An Independent Analysis of the FDA-Commissioned NASEM Report was commissioned by the Pharmacy Compounding Foundation.
(The 42-page paper is available at A4PC.org/BRGwhitepaper; a two-page synopsis is available on A4PC.org/cbht.)
Source: FDA-funded report on compounded hormones is tainted, analysis shows A4PCnews